Iobenguane I-131 - Progenics Pharmaceuticals

Drug Profile

Iobenguane I-131 - Progenics Pharmaceuticals

Alternative Names: 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; Azedra; I-131 mIBG; Iobenguane I-131; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals
  • Class Antineoplastics; Iodobenzenes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Neuroblastoma; Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuroblastoma; Neuroendocrine tumours

Most Recent Events

  • 01 Nov 2016 Molecular Insight Pharmaceuticals initiates an expanded-access programme for Neuroendocrine tumours in USA (NCT02961491)
  • 05 May 2016 Progenics announces intention to submit NDA to US FDA in 2017
  • 12 Oct 2015 Efficacy data from a phase II trial in Neuroendocrine tumours released by Progenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top